Facebook picto   picto linkdink   picto tiwter


Sep 26, 2014
Ablatherm HIFU Technology Highlighted

EDAP's Ablatherm® HIFU Technology Highlighted at the World Congress of Endourology, Taiwan

EDAP TMS SA, the global leader in therapeutic ultrasound, announced that the growing interest in and acceptance of its Ablatherm®-HIFU technology was once again highlighted as a valuable treatment alternative for prostate cancer patients in a presentation at the World Congress of Endourology (WCE) in Taipei, Taiwan from September 3-7, 2014.

The use of High Intensity Focused Ultrasound (HIFU) technology in the treatment of prostate cancer was featured in a plenary session of the conference, moderated by long term Ablatherm-HIFU user, Dr. Christian Chaussy, Professor of Urology, University of Munich, Germany. Posters on the use of Ablatherm-HIFU highlighted the importance of imaging technologies to more effectively locate prostate cancer, enabling improvements in treatment efficacy and reductions in retreatment rates. Also presented were highly positive clinical results at 5 and 10 years, following HIFU treatment of advanced prostate cancer patients. These outstanding results provide advanced prostate cancer patients a clear and viable therapeutic alternative, avoiding or postponing hormonal treatments and their dramatic side effects.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "It is a well-deserved validation of Ablatherm HIFU to have it highlighted in such a prestigious international conference that is attended by urologists from around the world. Interest in HIFU in the treatment of prostate cancer is growing worldwide and EDAP, with its Ablatherm®-HIFU and Focal One® devices for the treatment of localized prostate cancer, is well positioned to address this highly prevalent global medical need."